Search

Your search keyword '"Antonarakis, Emmanuel S"' showing total 1,870 results
Start Over Author "Antonarakis, Emmanuel S"
1,870 results on '"Antonarakis, Emmanuel S"'

252. Case Series of Men with the Germline APCI1307K variant and Treatment-Emergent Neuroendocrine Prostate Cancer

Author

Economides, Minas P., Nakazawa, Mari, Lee, Jonathan W., Li, Xiaochun, Hollifield, Lucas, Chambers, Rachelle, Sarfaty, Michal, Goldberg, Judith D., Antonarakis, Emmanuel S., and Wise, David R.

Abstract

•The APCI1307K germline variant is present in 7% of the Ashkenazi Jewish population and is associated with the development of several malignancies.•We report a case series of advanced prostate cancer patients with the germline APCI1307K mutation.•Prevalence of aggressive variant prostate cancer (driven by increased treatment-emergent neuroendocrine prostate cancer rate) in patients with the germline APCI1307K mutation is increased when compared to patients with prostate cancer and canonical APCframeshift mutations.•Prevalence of ARgenomic alterations in this cohort is lower than in unselected men with metastatic prostate cancer identified from cBioPortal database.

Published
2024
Full Text
View/download PDF

253. Baseline serum testosterone and differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial

Author

Kanayama, Mayuko, Tsai, Hua-Ling, Wang, Hao, Antonarakis, Emmanuel S., Denmeade, Samuel R., and Luo, Jun

Abstract

Bipolar androgen therapy (BAT) is effective in a subset of metastatic castration-resistant prostate cancer (mCRPC) patients. Treatment selection biomarkers are needed due to other therapies that can be equally efficacious. We performed post-hoc analysis to determine whether baseline serum testosterone (T) is a treatment selection marker in the TRANSFORMER study, a randomized trial of abiraterone-pretreated mCRPC patients assigned to BAT (n= 94) or enzalutamide (n= 101). The findings suggest that patients with poor outcomes to abiraterone and serum T ≥ 20 ng/dL may benefit preferentially from BAT over enzalutamide. Baseline testosterone could be considered in the treatment selection process when BAT is an option.

Published
2024
Full Text
View/download PDF

254. Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study

Author

Graff, Julie N., Hoimes, Christopher J., Gerritsen, Winald R., Vaishampayan, Ulka N., Elliott, Tony, Hwang, Clara, ten Tije, Albert J., Omlin, Aurelius, McDermott, Raymond S., Fradet, Yves, Tagawa, Scott T., Kilari, Deepak, Ferrario, Cristiano, Uemura, Hiroji, Jones, Robert J., Fukasawa, Satoshi, Peer, Avivit, Niu, Cuizhen, Poehlein, Christian H., Qiu, Ping, Suttner, Leah, de Wit, Ronald, Schloss, Charles, de Bono, Johann S., and Antonarakis, Emmanuel S.

Abstract

Background: KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study evaluating pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from cohorts 4 (C4) and 5 (C5) are presented. Methods: Eligible patients had not received chemotherapy for mCRPC and had responded to enzalutamide prior to developing resistance as defined by Prostate Cancer Clinical Trials Working Group 3 guidelines. Patients with RECIST-measurable disease were enrolled in C4, and patients with bone-only or bone-predominant disease were enrolled in C5. All patients received pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal. The primary end point was objective response rate (ORR) per RECIST v1.1 by blinded independent central review in C4. Secondary end points included disease control rate (DCR), overall survival, and safety in each cohort and both cohorts combined. Results: A total of 126 patients were treated (C4, n= 81; C5, n= 45). Median age was 72 years (range 43–92), and 87.3% had received ≥6 months of enzalutamide prior to study entry. Confirmed ORR was 12.3% (95% CI 6.1–21.5%) for C4. Median duration of response in C4 was 8.1 months (range, 2.5+ to 15.2), and 5 of these patients experienced an objective response lasting ≥6 months. DCR was 53.1% (95% CI 41.7–64.3%) in C4 and 51.1% (95% CI 35.8–66.3%) in C5. Median overall survival was 17.6 months (95% CI 14.0–22.6) in C4 and 20.8 months (95% CI 14.1–28.9) in C5. Grade ≥3 treatment-related adverse events occurred in 35 patients (27.8%); 2 patients in C4 died from immune-related adverse events (myasthenic syndrome and Guillain-Barré syndrome). Conclusions: The addition of pembrolizumab to ongoing enzalutamide treatment in patients with mCRPC that progressed on enzalutamide after initial response demonstrated modest antitumor activity with a manageable safety profile. Clinical trial registry and ID: ClinicalTrials.gov, NCT02787005.

Published
2024
Full Text
View/download PDF

255. Natural Killer Cell Infiltration in Prostate Cancers Predict Improved Patient Outcomes

Author

Zorko, Nicholas A., Makovec, Allison, Elliott, Andrew, Kellen, Samuel, Lozada, John R., Arafa, Ali T., Felices, Martin, Shackelford, Madison, Barata, Pedro, Zakharia, Yousef, Narayan, Vivek, Stein, Mark N., Zarrabi, Kevin K., Patniak, Akash, Bilen, Mehmet A., Radovich, Milan, Sledge, George, El-Deiry, Wafik S., Heath, Elisabeth I., Hoon, Dave S. B., Nabhan, Chadi, Miller, Jeffrey S., Hwang, Justin H., and Antonarakis, Emmanuel S.

Abstract

Background: Natural killer (NK) cells are non-antigen specific innate immune cells that can be redirected to targets of interest using multiple strategies, although none are currently FDA-approved. We sought to evaluate NK cell infiltration into tumors to develop an improved understanding of which histologies may be most amenable to NK cell-based therapies currently in the developmental pipeline. Methods: DNA (targeted/whole-exome) and RNA (whole-transcriptome) sequencing was performed from tumors from 45 cancer types (N= 90,916 for all cancers and N= 3365 for prostate cancer) submitted to Caris Life Sciences. NK cell fractions and immune deconvolution were inferred from RNA-seq data using quanTIseq. Real-world overall survival (OS) and treatment status was determined and Kaplan–Meier estimates were calculated. Statistical significance was determined using X2and Mann–Whitney Utests, with corrections for multiple comparisons where appropriate. Results: In both a pan-tumor and prostate cancer (PCa) -specific setting, we demonstrated that NK cells represent a substantial proportion of the total cellular infiltrate (median range 2–9% for all tumors). Higher NK cell infiltration was associated with improved OS in 28 of 45 cancer types, including (PCa). NK cell infiltration was negatively correlated with common driver mutations and androgen receptor variants (AR-V7) in primary prostate biopsies, while positively correlated with negative immune regulators. Higher levels of NK cell infiltration were associated with patterns consistent with a compensatory anti-inflammatory response. Conclusions: Using the largest available dataset to date, we demonstrated that NK cells infiltrate a broad range of tumors, including both primary and metastatic PCa. NK cell infiltration is associated with improved PCa patient outcomes. This study demonstrates that NK cells are capable of trafficking to both primary and metastatic PCa and are a viable option for immunotherapy approaches moving forward. Future development of strategies to enhance tumor-infiltrating NK cell-mediated cytolytic activity and activation while limiting inhibitory pathways will be key.

Published
2024
Full Text
View/download PDF

260. Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2 ‐mutated metastatic castrate‐resistant prostate cancer

Author

Su, Christopher T., primary, Nizialek, Emily, additional, Berchuck, Jacob E., additional, Vlachostergios, Panagiotis J., additional, Ashkar, Ryan, additional, Sokolova, Alexandra, additional, Barata, Pedro C., additional, Aggarwal, Rahul R., additional, McKay, Rana R., additional, Agarwal, Neeraj, additional, McClure, Heather M., additional, Nafissi, Nellie, additional, Bryce, Alan H., additional, Sartor, Oliver, additional, Sayegh, Nicolas, additional, Cheng, Heather H., additional, Adra, Nabil, additional, Sternberg, Cora N., additional, Taplin, Mary‐Ellen, additional, Cieslik, Marcin, additional, Alva, Ajjai S., additional, and Antonarakis, Emmanuel S., additional

Published
2022
Full Text
View/download PDF

262. Integrative molecular analyses define correlates of high B7-H3 expression in metastatic castrate-resistant prostate cancer

Author

Shi, Xiaolei, primary, Day, Abderrahman, additional, Bergom, Hannah E., additional, Tape, Sydney, additional, Baca, Sylvan C., additional, Sychev, Zoi E., additional, Larson, Gabrianne, additional, Bozicevich, Asha, additional, Drake, Justin M., additional, Zorko, Nicholas, additional, Wang, Jinhua, additional, Ryan, Charles J., additional, Antonarakis, Emmanuel S., additional, and Hwang, Justin, additional

Published
2022
Full Text
View/download PDF

263. Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials

Author

Deek, Matthew P., primary, Van der Eecken, Kim, additional, Sutera, Philip, additional, Deek, Rebecca A., additional, Fonteyne, Valérie, additional, Mendes, Adrianna A., additional, Decaestecker, Karel, additional, Kiess, Ana Ponce, additional, Lumen, Nicolaas, additional, Phillips, Ryan, additional, De Bruycker, Aurélie, additional, Mishra, Mark, additional, Rana, Zaker, additional, Molitoris, Jason, additional, Lambert, Bieke, additional, Delrue, Louke, additional, Wang, Hailun, additional, Lowe, Kathryn, additional, Verbeke, Sofie, additional, Van Dorpe, Jo, additional, Bultijnck, Renée, additional, Villeirs, Geert, additional, De Man, Kathia, additional, Ameye, Filip, additional, Song, Daniel Y., additional, DeWeese, Theodore, additional, Paller, Channing J., additional, Feng, Felix Y., additional, Wyatt, Alexander, additional, Pienta, Kenneth J., additional, Diehn, Maximillian, additional, Bentzen, Soren M., additional, Joniau, Steven, additional, Vanhaverbeke, Friedl, additional, De Meerleer, Gert, additional, Antonarakis, Emmanuel S., additional, Lotan, Tamara L., additional, Berlin, Alejandro, additional, Siva, Shankar, additional, Ost, Piet, additional, and Tran, Phuoc T., additional

Published
2022
Full Text
View/download PDF

266. SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis–Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer

Author

Swami, Umang, primary, Graf, Ryon P., additional, Nussenzveig, Roberto H., additional, Fisher, Virginia, additional, Tukachinsky, Hanna, additional, Schrock, Alexa B., additional, Li, Gerald, additional, Ross, Jeffrey S., additional, Sayegh, Nicolas, additional, Tripathi, Nishita, additional, Mathew Thomas, Vinay, additional, Oxnard, Geoffrey R., additional, Antonarakis, Emmanuel S., additional, and Agarwal, Neeraj, additional

Published
2022
Full Text
View/download PDF

270. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.

Author

Antonarakis, Emmanuel S., Park, Se Hoon, Goh, Jeffrey C., Shin, Sang Joon, Lee, Jae Lyun, Mehra, Niven, McDermott, Ray, Sala-Gonzalez, Núria, Fong, Peter C., Greil, Richard, Retz, Margitta, Sade, Juan Pablo, Yanez, Patricio, Huang, Yi-Hsiu, Begbie, Stephen D., Gafanov, Rustem Airatovich, De Santis, Maria, Rosenbaum, Eli, Kolinsky, Michael P., and Rey, Felipe

Published
2023
Full Text
View/download PDF

271. Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).

Author

Morris, Michael J., Heller, Glenn, Hillman, David W., Bobek, Olivia, Ryan, Charles, Antonarakis, Emmanuel S., Bryce, Alan H., Hahn, Olwen, Beltran, Himisha, Armstrong, Andrew J., Schwartz, Lawrence, Lewis, Lionel D., Beumer, Jan H., Langevin, Brooke, McGary, Eric C., Mehan, Paul T., Goldkorn, Amir, Roth, Bruce J., Xiao, Han, and Watt, Colleen

Published
2023
Full Text
View/download PDF

279. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies

Author

Zurita, Amado J., primary, Graf, Ryon P., additional, Villacampa, Guillermo, additional, Raskina, Kira, additional, Sokol, Ethan, additional, Jin, Dexter, additional, Antonarakis, Emmanuel S., additional, Li, Gerald, additional, Huang, Richard S. P., additional, Casanova-Salas, Irene, additional, Vivancos, Ana, additional, Carles, Joan, additional, Ross, Jeffrey S., additional, Schrock, Alexa B., additional, Oxnard, Geoffrey R., additional, and Mateo, Joaquin, additional

Published
2022
Full Text
View/download PDF

280. Abstract 646: Liquid biopsy transcriptomics identify pathways associated with poor outcomes and immune phenotypes in men with mCRPC

Author

Zhang, Jiaren, primary, Zimmermann, Bob, additional, Galletti, Giuseppe, additional, Halabi, Susan, additional, Gjyrezi, Ada, additional, Yang, Qian, additional, Gupta, Santosh, additional, Verma, Akanksha, additional, Sboner, Andrea, additional, Anand, Monika, additional, George, Daniel J., additional, Gregory, Simon G., additional, Mahtani, Prerna, additional, Hong, Seunghee, additional, Pascual, Virginia, additional, Mavragani, Clio P., additional, Antonarakis, Emmanuel S., additional, Nanus, David M., additional, Tagawa, Scott T., additional, Elemento, Olivier, additional, Armstrong, Andrew J., additional, and Giannakakou, Paraskevi, additional

Published
2022
Full Text
View/download PDF

283. Genomic and immunologic profiles of concurrent RB1 and CDKN1A/p21(WAF1) truncating mutations (RW+) in bladder cancer.

Author

El-Deiry, Wafik S., primary, Arnoff, Taylor, additional, Carneiro, Benedito A., additional, DeSouza, Andre, additional, Amin, Ali, additional, Safran, Howard, additional, Heath, Elisabeth I., additional, Joshi, Monika, additional, Golijanin, Dragan, additional, Holder, Sheldon L., additional, Mega, Anthony E., additional, Khushman, Moh'd M., additional, Darabi, Sourat, additional, Antonarakis, Emmanuel S., additional, Saeed, Anwaar, additional, Lou, Emil, additional, Farrell, Alex, additional, Yin, Jun, additional, Plimack, Elizabeth R., additional, and McKay, Rana R., additional

Published
2022
Full Text
View/download PDF

284. Molecular correlates of Delta-like-ligand 3 (DLL3) expression in neuroendocrine neoplasms (NENs).

Author

Hwang, Justin, primary, McGrath, Julie, additional, Lozada, John R, additional, Brodskiy, Pavel, additional, Xiu, Joanne, additional, Wei, Shuanzeng, additional, Heath, Elisabeth I., additional, Carneiro, Benedito A., additional, Lou, Emil, additional, Soares, Heloisa P., additional, McKay, Rana R., additional, Antonarakis, Emmanuel S., additional, Ryan, Charles J., additional, Spetzler, David, additional, and Beltran, Himisha, additional

Published
2022
Full Text
View/download PDF

285. Final analysis of the phase 1b/2 study of sabizabulin in men with metastatic castration-resistant prostate cancer who progressed on an androgen receptor targeting agent.

Author

Markowski, Mark Christopher, primary, Eisenberger, Mario A., additional, Pieczonka, Christopher Michael, additional, Getzenberg, Robert H., additional, Rodriguez, Domingo, additional, Barnette, K. Gary, additional, Steiner, Mitchell S., additional, Saltzstein, Daniel R., additional, Antonarakis, Emmanuel S., additional, and Tutrone, Ronald F., additional

Published
2022
Full Text
View/download PDF

286. Reversion mutations in BRCA1 or BRCA2 genes: Resistant mechanism(s) in patients treated with platinum-based agents or poly (ADP-ribose) polymerase(PARP) inhibitors.

Author

Darabi, Sourat, primary, Braxton, David R., additional, Xiu, Joanne, additional, Carneiro, Benedito A., additional, Swensen, Jeffrey, additional, Antonarakis, Emmanuel S., additional, Liu, Stephen V., additional, McKay, Rana R., additional, Spetzler, David, additional, El-Deiry, Wafik S., additional, and Demeure, Michael J., additional

Published
2022
Full Text
View/download PDF

289. Targeting B7-H3 in prostate cancer: Phase 2 trial in localized prostate cancer using the anti-B7-H3 antibody enoblituzumab, with biomarker correlatives.

Author

Shenderov, Eugene, primary, De Marzo, Angelo M, additional, Lotan, Tamara L., additional, Wang, Hao, additional, Lim, Su Jin, additional, Allaf, Mohamad E., additional, Moore, Paul A., additional, Chen, Francine, additional, Sorg, Kristina, additional, White, Andrew M, additional, Hudson, Briana, additional, Fields, Paul A., additional, Hu, Shaohui, additional, Denmeade, Samuel R., additional, Pienta, Kenneth J., additional, Pavlovich, Christian P., additional, Drake, Charles G., additional, Pardoll, Drew M., additional, and Antonarakis, Emmanuel S., additional

Published
2022
Full Text
View/download PDF

291. Overall survival (OS) and biomarker results from combat: A phase 2 study of bipolar androgen therapy (BAT) plus nivolumab for patients with metastatic castrate-resistant prostate cancer (mCRPC).

Author

Markowski, Mark Christopher, primary, Taplin, Mary-Ellen, additional, Aggarwal, Rahul Raj, additional, Sena, Laura, additional, Wang, Hao, additional, Lalji, Aliya, additional, Meyers, Jennifer, additional, Skaist, Alyza, additional, Gupta, Anuj, additional, Gomes-Alexandre, Carolina, additional, Jones, Tracy, additional, Hicks, Jessica, additional, Kachhap, Sushant, additional, Yegnasubramanian, Srinivasan, additional, De Marzo, Angelo M, additional, Denmeade, Samuel R., additional, and Antonarakis, Emmanuel S., additional

Published
2022
Full Text
View/download PDF

292. BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.

Author

Hussain, Maha H. A., primary, Kocherginsky, Masha, additional, Agarwal, Neeraj, additional, Zhang, Jingsong, additional, Adra, Nabil, additional, Paller, Channing Judith, additional, Picus, Joel, additional, Reichert, Zachery R, additional, Szmulewitz, Russell Zelig, additional, Tagawa, Scott T., additional, Whang, Young E., additional, Dreicer, Robert, additional, Kuzel, Timothy, additional, Bazzi, Latifa, additional, Gerke, Travis A., additional, Daignault-Newton, Stephanie, additional, Chinnaiyan, Arul, additional, and Antonarakis, Emmanuel S., additional

Published
2022
Full Text
View/download PDF

293. Phase II, double-blind, randomized study of salvage radiation therapy (SRT) plus enzalutamide or placebo for high-risk PSA-recurrent prostate cancer after radical prostatectomy: The SALV-ENZA Trial.

Author

Tran, Phuoc T., primary, Lowe, Kathryn, additional, Wang, Hao, additional, Tsai, Hua-Ling, additional, Song, Daniel Y., additional, Hung, Arthur, additional, Hearn, Jason W.D., additional, Lotan, Tamara L., additional, Paller, Channing Judith, additional, Markowski, Mark Christopher, additional, Denmeade, Samuel R., additional, Carducci, Michael Anthony, additional, Eisenberger, Mario A., additional, Orton, Matthew, additional, Deville, Curtiland, additional, Liauw, Stanley L., additional, Heath, Elisabeth I., additional, Desai, Neil B, additional, Beer, Tomasz M., additional, and Antonarakis, Emmanuel S., additional

Published
2022
Full Text
View/download PDF

294. Cooling inflammation while potentiating immune checkpoint inhibition: Enhancing the benefit-risk ratio of immuno-oncology therapy.

Author

Potter, David A., Zhijun Guo, Jianxun Lei, and Antonarakis, Emmanuel S.

Subjects
IMMUNE checkpoint inhibitors, DNA mismatch repair, INFLAMMATION, FATTY acid desaturase, PATHOLOGIC complete response, UNSATURATED fatty acids, HEAT stroke
Abstract

The article explores the potential advantages of combining immune checkpoint inhibition (ICI) with the inhibition of the soluble epoxide hydrolase (sEH) pathway in cancer immunotherapy. The authors suggest that this combination therapy could enhance the anti-tumor activity of cytotoxic T cells while also mitigating inflammatory toxicities. They also discuss the potential role of omega-3 fatty acids in creating an anti-inflammatory environment and their potential as a therapeutic strategy in combination with ICI. The article proposes conducting clinical trials to further investigate the efficacy and safety of this combination therapy in metastatic and prostate cancer. [Extracted from the article]

Published
2024
Full Text
View/download PDF

295. Management of patients with advanced prostate cancer. Part I: intermediate-/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022

Author

Tilki, Derya, Gillessen, Silke; Bossi, Alberto; Davis, Ian D.; de Bono, Johann; Fizazi, Karim; James, Nicholas D.; Mottet, Nicolas; Shore, Neal; Small, Eric; Smith, Mathew; Sweeney, Christopher; Tombal, Bertrand; Antonarakis, Emmanuel S.; Aparicio, Ana M.; Armstrong, Andrew J.; Attard, Gerhardt; Beer, Tomasz M.; Beltran, Himisha; Bjartell, Anders; Blanchard, Pierre; Briganti, Alberto; Bristow, Rob G.; Bulbul, Muhammad; Caffo, Orazio; Castellano, Daniel; Castro, Elena; Cheng, Heather H.; Chi, Kim N.; Chowdhury, Simon; Clarke, Caroline S.; Clarke, Noel; Daugaard, Gedske; De Santis, Maria; Duran, Ignacio; Eeles, Ros; Efstathiou, Eleni; Efstathiou, Jason; Ngozi Ekeke, Onyeanunam; Evans, Christopher P.; Fanti, Stefano; Feng, Felix Y.; Fonteyne, Valerie; Fossati, Nicola; Frydenberg, Mark; George, Daniel; Gleave, Martin; Gravis, Gwenaelle; Halabi, Susan; Heinrich, Daniel; Herrmann, Ken; Higano, Celestia; Hofman, Michael S.; Horvath, Lisa G.; Hussain, Maha; Jereczek-Fossa, Barbara Alicja; Jones, Robert; Kanesvaran, Ravindran; Kellokumpu-Lehtinen, Pirkko-Liisa; Khauli, Raja B.; Klotz, Laurence; Kramer, Gero; Leibowitz, Raya; Logothetis, Christopher J.; Mahal, Brandon A.; Maluf, Fernando; Mateo, Joaquin; Matheson, David; Mehra, Niven; Merseburger, Axel; Morgans, Alicia K.; Morris, Michael J.; Mrabti, Hind; Mukherji, Deborah; Murphy, Declan G.; Murthy, Vedang; Nguyen, Paul L.; Oh, William K.; Ost, Piet; O'Sullivan, Joe; Padhani, Anwar R.; Pezaro, Carmel; Poon, Darren M.C.; Pritchard, Colin C.; Rabah, Danny M.; Rathkopf, Dana; Reiter, Robert E.; Rubin, Mark. A.; Ryan, Charles J.; Saad, Fred; Pablo Sade, Juan; Sartor, Oliver A.; Scher, Howard I.; Sharifi, Nima; Skoneczna, Iwona; Soule, Howard; Spratt, Daniel E.; Srinivas, Sandy; Sternberg, Cora N.; Steuber, Thomas; Suzuki, Hiroyoshi; Sydes, Matthew R.; Taplin, Mary-Ellen; Türkeri, Levent; Turco, Fabio; Uemura, Hiroji; Uemura, Hirotsugu; Ürün, Yüksel; Vale, Claire L.; van Oort, Inge; Vapiwala, Neha; Walz, Jochen; Yamoah, Kosj; Ye, Dingwei; Yu, School of Medicine, Tilki, Derya, Gillessen, Silke; Bossi, Alberto; Davis, Ian D.; de Bono, Johann; Fizazi, Karim; James, Nicholas D.; Mottet, Nicolas; Shore, Neal; Small, Eric; Smith, Mathew; Sweeney, Christopher; Tombal, Bertrand; Antonarakis, Emmanuel S.; Aparicio, Ana M.; Armstrong, Andrew J.; Attard, Gerhardt; Beer, Tomasz M.; Beltran, Himisha; Bjartell, Anders; Blanchard, Pierre; Briganti, Alberto; Bristow, Rob G.; Bulbul, Muhammad; Caffo, Orazio; Castellano, Daniel; Castro, Elena; Cheng, Heather H.; Chi, Kim N.; Chowdhury, Simon; Clarke, Caroline S.; Clarke, Noel; Daugaard, Gedske; De Santis, Maria; Duran, Ignacio; Eeles, Ros; Efstathiou, Eleni; Efstathiou, Jason; Ngozi Ekeke, Onyeanunam; Evans, Christopher P.; Fanti, Stefano; Feng, Felix Y.; Fonteyne, Valerie; Fossati, Nicola; Frydenberg, Mark; George, Daniel; Gleave, Martin; Gravis, Gwenaelle; Halabi, Susan; Heinrich, Daniel; Herrmann, Ken; Higano, Celestia; Hofman, Michael S.; Horvath, Lisa G.; Hussain, Maha; Jereczek-Fossa, Barbara Alicja; Jones, Robert; Kanesvaran, Ravindran; Kellokumpu-Lehtinen, Pirkko-Liisa; Khauli, Raja B.; Klotz, Laurence; Kramer, Gero; Leibowitz, Raya; Logothetis, Christopher J.; Mahal, Brandon A.; Maluf, Fernando; Mateo, Joaquin; Matheson, David; Mehra, Niven; Merseburger, Axel; Morgans, Alicia K.; Morris, Michael J.; Mrabti, Hind; Mukherji, Deborah; Murphy, Declan G.; Murthy, Vedang; Nguyen, Paul L.; Oh, William K.; Ost, Piet; O'Sullivan, Joe; Padhani, Anwar R.; Pezaro, Carmel; Poon, Darren M.C.; Pritchard, Colin C.; Rabah, Danny M.; Rathkopf, Dana; Reiter, Robert E.; Rubin, Mark. A.; Ryan, Charles J.; Saad, Fred; Pablo Sade, Juan; Sartor, Oliver A.; Scher, Howard I.; Sharifi, Nima; Skoneczna, Iwona; Soule, Howard; Spratt, Daniel E.; Srinivas, Sandy; Sternberg, Cora N.; Steuber, Thomas; Suzuki, Hiroyoshi; Sydes, Matthew R.; Taplin, Mary-Ellen; Türkeri, Levent; Turco, Fabio; Uemura, Hiroji; Uemura, Hirotsugu; Ürün, Yüksel; Vale, Claire L.; van Oort, Inge; Vapiwala, Neha; Walz, Jochen; Yamoah, Kosj; Ye, Dingwei; Yu, and School of Medicine

Abstract

Background: innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. Objective: to present consensus voting results for select questions from APCCC 2022. Design, setting, and participants: before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members (“panellists”) who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1–3. Outcome measurements and statistical analysis: consensus was defined as ?75% agreement, with strong consensus defined as ?90% agreement. Results and limitations: the voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. Conclusions: these voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical manage, We gratefully acknowledge the following organisations for providing financial support for the APCCC 2022: The City of Lugano and Movember Foundation. Ros Eeles is supported by a National Institute of Health Research grant to the Biomedical Research Centre at The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. We also acknowledge sponsorship from several for-profit organisations for APCCC 2022, including Advanced Accelerator Applications, Amgen, Astellas, AstraZeneca, Bayer Health Care, Debio-pharm, MSD, Janssen Oncology, Myovant Sciences, Orion Pharma, Pfizer Oncology, Roche, Telix Innovations SA, Ferring Pharmaceuticals, Lantheus, and Tolmar. These for-profit organisations supported the conference financially but had no input on the scientific content or the final publication.

Published
2022

298. Prostate cancer androgen receptor activity dictates efficacy of Bipolar Androgen Therapy

Author

Sena, Laura A, primary, Kumar, Rajendra, additional, Sanin, David E, additional, Thompson, Elizabeth A, additional, Rosen, D Marc, additional, Dalrymple, Susan L, additional, Antony, Lizamma, additional, Yang, Yuhan, additional, Gomes-Alexandre, Carolina, additional, Hicks, Jessica L, additional, Jones, Tracy, additional, Bowers, Kiara A., additional, Eskra, Jillian N, additional, Meyers, Jennifer, additional, Gupta, Anuj, additional, Skaist, Alyza, additional, Yegnasubramanian, Srinivasan, additional, Luo, Jun, additional, Brennen, W Nathaniel, additional, Kachhap, Sushant K, additional, Antonarakis, Emmanuel S, additional, De Marzo, Angelo M, additional, Isaacs, John T, additional, Markowski, Mark C, additional, and Denmeade, Samuel R, additional

Published
2022
Full Text
View/download PDF

299. A Phase Ib/II Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men with Metastatic Castration-resistant Prostate Cancer with Progression on an Androgen Receptor–targeting Agent

Author

Markowski, Mark C., primary, Tutrone, Ronald, additional, Pieczonka, Christopher, additional, Barnette, K. Gary, additional, Getzenberg, Robert H., additional, Rodriguez, Domingo, additional, Steiner, Mitchell S., additional, Saltzstein, Daniel R., additional, Eisenberger, Mario A., additional, and Antonarakis, Emmanuel S., additional

Published
2022
Full Text
View/download PDF

300. Extreme Responses to a Combination of DNA-Damaging Therapy and Immunotherapy in CDK12-Altered Metastatic Castration-Resistant Prostate Cancer: A Potential Therapeutic Vulnerability

Author

Gongora, Aline B.L., primary, Marshall, Catherine H, additional, Velho, Pedro Isaacsson, additional, Lopes, Carlos D.H., additional, Marin, José F., additional, Camargo, Anamaria A., additional, Bastos, Diogo A., additional, and Antonarakis, Emmanuel S., additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results